Sorafenib inhibits tumor cell proliferation by targeting the Raf/mitogen-activated protein kinase/extracellular signal-regulated kinase (Raf/MEK/ERK) signaling pathway and exerts an antiangiogenic effect by targeting a number of tyrosine kinases: Vascular endothelial growth factor-2 (VEGFR-2), VEGFR-3 and platelet-derived growth factor receptor-β (100,101). The gene discussed is MAP2K7; the disease is neoplasm.